Skip to content

Psilocybin: all studies

Page 320 of 439: studies 3,191 to 3,200 of 4,389, newest first. Back to the psilocybin overview

Research

A psychedelic research agenda? The quest for therapeutic and legal legitimacy

Edward Elgar Publishing eBooks January 20, 2026 Muireann Quigley, Matt Hayler

In this chapter, we consider the therapeutic potential of psychedelics, such as psilocybin and midomafetamine (MDMA), as a novel response to deepening mental health crises. In particular, we examine this in the context of restrictive drug control systems across Europe (including the United Kingdom). Whilst promising results from several clinical studies have fed into and helped to perpetuate a...

Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms

Journal of Affective Disorders January 19, 2026 Maria Garcia Garcia, Dahbia Belahda, Carine Graux et al.

Responders were distinguished by narratives of inner dialogue and adaptive coping, while non-responders emphasized sensory and affective descriptions and suppressive coping. Inner dialogue may constitute a distinct therapeutic mechanism, highlighting the importance of preparation and integration in psilocybin-assisted psychotherapy.

Correction to “Anthropology of Psychedelics”

Anthropology of Consciousness January 18, 2026 correction

Falcon, J. 2025. “Anthropology of Psychedelics.” Anthropology of Consciousness 36: e70002, 1-14 https://doi.org/10.1111/anoc.70002. In Paragraph 1 of the “Psilocybin” section, the sentence “Although it is difficult to find archaeological evidence of their use in prehistory, some estimate their use may date as far back as 40 000 years based on cave paintings found in Algeria (Froese et al....

DOI: 10.1111/anoc.70030 (opens in new tab) Paragraph Sentence Cave painting Archaeology

Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data.

CNS Drugs January 17, 2026 Gaëlle Rached, Anna Campana, Dimitri Fiani et al. 1 citation

Monoamine oxidase inhibitors (MAOIs) remain an important option for patients with treatment-resistant depression (TRD) and other psychiatric conditions, despite potentially serious drug-drug interactions and associated dietary tyramine restrictions. However, they are rarely prescribed in patients with comorbid substance use disorders (SUDs) due to concerns about potential drug interactions and...

Psychedelics distinctly alter brain entropy and complexity compared to psychostimulants

medRxiv January 16, 2026 Kristian Larsen, Patrick M. Fisher, Drummond E. Mcculloch et al. 1 citation preprint

Classical psychedelics have regained interest for their potential to treat psychiatric and neurological disorders, and explore neural mechanisms supporting perception, cognition, and mood. Acute psychedelic effects have been linked to increases in brain complexity and entropy, but it is unclear if these changes are specific to psychedelics or reflect more general psychoactive effects. Here, we...

Psilocibina como ferramenta terapêutica em transtornos depressivos em adultos: uma revisão sistemática das evidências e impactos

Brazilian Journal of Implantology and Health Sciences January 15, 2026 Bianca Gasparotto da Silva, Giovana Labegaline Araújo, Bruna Rafaela Prestes et al.

Os transtornos depressivos representam uma das principais causas de incapacidade global, afetando de forma significativa o funcionamento emocional, social e ocupacional dos indivíduos. Apesar da ampla disponibilidade de antidepressivos convencionais, muitos pacientes apresentam resposta insuficiente ou efeitos adversos limitantes, especialmente aqueles com depressão resistente ao tratamento...

Chemical Design and Pharmacokinetics Enable Precision Psychedelic Therapeutics.

ACS Medicinal Chemistry Letters January 12, 2026 Anna C. Renner, Robert B. Kargbo

Recent psychedelic patent activity highlights a strategic shift from experiential framing toward chemically and pharmacokinetically precise neurotherapeutics. Four recent patent applications collectively span solid-state control of psilocybin, exposure-shaped intramuscular and infusion-based dosing, and chemically diversified monoaminergic scaffolds with defined transporter and receptor...

The mushrooming of the psychedelic renaissance: A scoping review identifying trends in ongoing clinical trials

Research Square January 12, 2026 Lucas M Wittenkeller, Gary A. Gudelsky, T. John Winhusen et al. preprint

Abstract Aims: The investigation of psychedelics as potential therapies has expanded dramatically in the past decade, leading to their study in a wide range of conditions. Here, we characterize all ongoing clinical trials utilizing a psychedelic intervention with the goals of identifying trends in experimental design and application and discuss how findings from individual, ongoing clinical...

DOI: 10.21203/rs.3.rs-8544354/v1 (opens in new tab) Full text (opens in new tab) Clinical trial Blinding Intervention counseling Alternative medicine +7

Presence of 4-Hydroxy- N -methyl- N -ethyltryptamine in Commercially Available Products

ACS Omega January 7, 2026 Ana Barovic, Monica Pittiglio, Justin Barrett et al.

High Resolution Image Download MS PowerPoint Slide Novel psychoactive substances (NPS) remain an ongoing challenge for public health, forensic laboratories, and regulatory agencies, especially when they are chemically related to controlled tryptamines but are marketed as legal alternatives. In the United States, the Federal Analogue Act (FAA) was intended to restrict such substances; however,...

DOI: 10.1021/acsomega.5c10889 (opens in new tab) Tryptamines Synthetic cannabinoids Gas chromatography–mass spectrometry

Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model.

ACS Chemical Neuroscience January 7, 2026 Charalampos L. Kandilakis, Costas Papatheodoropoulos

Psychedelics are a diverse class of psychoactive compounds that profoundly alter perception, cognition, and emotional states. Recently, classical serotonergic agents, such as psilocybin and lysergic acid diethylamide (LSD), along with atypical agents such as methylenedioxymethamphetamine (MDMA, ecstasy) and ibogaine, have attracted renewed attention due to their rapid and sustained clinical...